PU.1-dependent regulation of UCH L1 expression in B-lymphoma cells

Leukemia and Lymphoma

Volumn 52, Issue 7, 2011, Pages 1336-1347

  Bheda, Anjali ^a   Yue, Wei ^a   Gullapalli, Anuradha ^a   Shackelford, Julia ^a,b   Pagano, Joseph S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

lymphomas; Transcription factor PU.1; ubiquitin C terminal hyrolase L1

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 2; ONCOPROTEIN; TRANSCRIPTION FACTOR PU 1; UBIQUITIN CARBOXYL TERMINAL HYDROLASE L1; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; BINDING SITE; BURKITT LYMPHOMA; CANCER GROWTH; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EPITHELIUM CELL; EPSTEIN BARR VIRUS; FEMALE; FIBROBLAST; HELA CELL; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; LYMPHOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; UPREGULATION;

BINDING SITES; BURKITT LYMPHOMA; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA, B-CELL; MODELS, BIOLOGICAL; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; TRANS-ACTIVATORS; UBIQUITIN THIOLESTERASE; UP-REGULATION;

EID: 79959625605     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.562571     Document Type: Article

References (61)

1. Ventii KH, Wilkinson KD. Protein partners of deubiquitinating enzymes. Biochem J 2008;414:161-175.
2. Larsen CN, Price JS, Wilkinson KD. Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues. Biochemistry 1996;35:6735-6744. (Pubitemid 26172432)
3. Betarbet R, Sherer TB, Greenamyre JT. Ubiquitin-proteasome system and Parkinson's diseases. Exp Neurol 2005;191(Suppl. 1):S17-S27.
4. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT Jr. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 2002;111:209-218. (Pubitemid 35292441)
5. Setsuie R, Wada K. The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int 2007;51:105-111. (Pubitemid 47179898)
6. Kabuta T, Setsuie R, Mitsui T, et al. Aberrant molecular properties shared by familial Parkinson's disease-associated mutant UCH-L1 and carbonyl-modified UCH-L1. Hum Mol Genet 2008;15:1482-1496. (Pubitemid 351627344)
7. Bheda A, Gullapalli A, Caplow M, Pagano JS, Shackelford J. Ubiquitin editing enzyme UCH L1 and microtubule dynamics: implication in mitosis. Cell Cycle 2010;9:980-994.
8. Basseres E, Coppotelli G, Pfirrmann T, Andersen JB, Masucci M, Frisan T. The ubiquitin C-terminal hydrolase UCH-L1 promotes bacterial invasion by altering the dynamics of the actin cytoskeleton. Cell Microbiol 2010;12 1622-1633.
9. Hibi K, Westra WH, Borges M, Goodman S, Sidransky D, Jen J. PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. Am J Pathol 1999;155:711-715. (Pubitemid 29426816)
10. Loeffler-Ragg J, Skvortsov S, Sarg B, et al. Gefitinibresponsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines. Eur J Cancer 2005;41:2338-2346. (Pubitemid 41415611)
11. Yang YC, Li X, Chen W. Characterization of genes associated with different phenotypes of human bladder cancer cells. Acta Biochim Biophys Sin (Shanghai) 2006;38:602-610. (Pubitemid 44395194)
12. Miyoshi Y, Nakayama S, Torikoshi Y, et al. High expression of ubiquitin carboxy-terminal hydrolase-L1 and -L3 mRNA predicts early recurrence in patients with invasive breast cancer. Cancer Sci 2006;97:523-529. (Pubitemid 43811594)
13. Rolen U, Freda E, Xie J, Pfirmann T, Frisan T, Masucci MG. The ubiquitin C-terminal hydrolase UCH-L1 regulates B-cell proliferation and integrin activation. J Cell Mol Med 2009;13:1666-1678.
14. Bheda A, Shackelford J, Pagano JS. Expression and functional studies of ubiquitin C-terminal hydrolase L1 regulated genes. PLoS One 2009;4:e6764.
15. Kim HJ, Kim YM, Lim S, et al. Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis. Oncogene 2009;28:117-127.
16. Hussain S, Foreman O, Perkins SL, et al. The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling. Leukemia 2010;24:1641-1655.
17. Mann DA, Trowern AR, Lavender FL, Whittaker PA, Thompson RJ. Identification of evolutionary conserved regulatory sequences in the 50 untranscribed region of the neural-specific ubiquitin C-terminal hydrolase (PGP9.5) gene. J Neurochem 1996;66:35-46.
18. Long EM, Long MA, Tsirigotis M, Gray DA. Stimulation of the murine Uchl1 gene promoter by the B-Myb transcription factor. Lung Cancer 2003;42:9-21. (Pubitemid 37153131)
19. Bheda A, Yue W, Gullapalli A, et al. Positive reciprocal regulation of ubiquitin C-terminal hydrolase L1 and betacatenin/ TCF signaling. PLoS One 2009;4:e5955.
20. Hussain S, Zhang Y, Galardy PJ. DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors. Cell Cycle 2009;8:1688-1697.
21. Moreau-Gachelin F. Spi-1/PU.1: an oncogene of the Ets family. Biochim Biophys Acta 1994;1198:149-163.
22. Dakic A, Wu L, Nutt SL. Is PU.1 a dosage-sensitive regulator of haemopoietic lineage commitment and leukaemogenesis? Trends Immunol 2007;28:108-114. (Pubitemid 46283693)
23. Fisher RC, Scott EW. Role of PU.1 in hematopoiesis. Stem Cells 1998;16:25-37. (Pubitemid 28065328)
24. Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 1994;265:1573-1577.
25. Singh H, DeKoter RP, Walsh JC. PU.1, a shared transcriptional regulator of lymphoid and myeloid cell fates. Cold Spring Harb Symp Quant Biol 1999;64:13-20. (Pubitemid 30329258)
26. Moreau-Gachelin F. Multi-stage Friend murine erythroleukemia: molecular insights into oncogenic cooperation. Retrovirology 2008;5:99.
27. Moreau-Gachelin F. Lessons from models of murine erythroleukemia to acute myeloid leukemia (AML): proof-ofprinciple of co-operativity in AML. Haematologica 2006;91:1644-1652. (Pubitemid 46032962)
28. McCune RC, Syrbu SI, Vasef MA. Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB.1, and PU.1 in Hodgkin's and non-Hodgkin's lymphomas: a comparative study using high throughput tissue microarrays. Mod Pathol 2006;19:1010-1018.
29. Loddenkemper C, Anagnostopoulos I, Hummel M, et al. Differential Emu enhancer activity and expression of BOB.1/ OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. J Pathol 2004;202:60-69. (Pubitemid 38072846)
30. Pagano J. Epstein-Barr virus diseases. In: Damania B, Pipas J, editors.DNAtumor viruses. New York: Springer; 2009. Ch 10.
31. Cohen JI, Bollard CM, Khanna R, Pittaluga S. Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leuk Lymphoma 2008;49(Suppl. 1):27-34.
32. Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 2003;3:801-812. (Pubitemid 37328658)
33. Kempkes B, Spitkovsky D, Jansen-Durr P, et al. B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J 1995;14:88-96.
34. Sjoblom A, Jansson A, Yang W, Lain S, Nilsson T, Rymo L. PU box-binding transcription factors and a POU domain protein cooperate in the Epstein-Barr virus (EBV) nuclear antigen 2-induced transactivation of the EBV latent membrane protein 1 promoter. J Gen Virol 1995;76:2679-2692.
35. Sjoblom A, Nerstedt A, Jansson A, Rymo L. Domains of the Epstein-Barr virus nuclear antigen 2 (EBNA2) involved in the transactivation of the latent membrane protein 1 and the EBNA Cp promoters. J Gen Virol 1995;76:2669-2678.
36. Gordadze AV, Onunwor CW, Peng R, Poston D, Kremmer E, Ling PD. EBNA2 amino acids 3 to 30 are required for induction of LMP-1 and immortalization maintenance. J Virol 2004;78:3919-3929. (Pubitemid 38437198)
37. Petrovick MS, Hiebert SW, Friedman AD, Hetherington CJ, Tenen DG, Zhang DE. Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1. Mol Cell Biol 1998;18:3915-3925. (Pubitemid 28287915)
38. Chang HC, Zhang S, Thieu VT, et al. PU.1 expression delineates heterogeneity in primary Th2 cells. Immunity 2005;22:693-703. (Pubitemid 40814500)
39. Hu R, Sharma SM, Bronisz A, Srinivasan R, Sankar U, Ostrowski MC. Eos, MITF, and PU.1 recruit corepressors toosteoclast-specific genes in committed myeloid progenitors. Mol Cell Biol 2007;27:4018-4027. (Pubitemid 47010999)
40. Lennartsson A, Garwicz D, Lindmark A, Gullberg U. The proximal promoter of the human cathepsin G gene conferring myeloid-specific expression includes C/EBP, c-myb and PU.1 binding sites. Gene 2005;356:193-202. (Pubitemid 41175985)
41. Ovaa H, Kessler BM, Rolen U, Galardy PJ, Ploegh HL, Masucci MG. Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells. Proc Natl Acad Sci USA 2004;101:2253-2258. (Pubitemid 38269298)
42. Tatsumi E. Epstein-Barr virus (EBV) and human hematopoietic cell lines: a review. Hum Cell 1992;5:79-86.
43. Nasr MR, Rosenthal N, Syrbu S. Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/ lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker. Am J Clin Pathol 2010;133:41-48.
44. Siemer D, Kurth J, Lang S, Lehnerdt G, Stanelle J, Kuppers R. EBV transformation overrides gene expression patterns of B cell differentiation stages. Mol Immunol 2008;45:3133-3141.
45. Nutt SL, Kee BL. The transcriptional regulation of B cell lineage commitment. Immunity 2007;26:715-725. (Pubitemid 46908962)
46. Bheda A, Creek KE, Pirisi L. Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes. Oncogene 2008;27:4315-4323. (Pubitemid 352009996)
47. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 2003;22:5108-5121. (Pubitemid 37059592)
48. Gupta P, Gurudutta GU, Saluja D, Tripathi RP. PU.1 and partners: regulation of haematopoietic stem cell fate in normal and malignant haematopoiesis. J Cell Mol Med 2009;13: 4349-4363.
49. Laux G, Adam B, Strobl LJ, Moreau-Gachelin F. The Spi-1/ PU.1 and Spi-B ets family transcription factors and the recombination signal binding protein RBP-J kappa interact with an Epstein-Barr virus nuclear antigen 2 responsive cis-element. EMBO J 1994;13:5624-5632. (Pubitemid 24363030)
50. Bornkamm GW. Epstein-Barr virus and its role in the pathogenesis of Burkitt's lymphoma: an unresolved issue. Semin Cancer Biol 2009;19:351-365.
51. Bornkamm GW. Epstein-Barr virus and the pathogenesis of Burkitt's lymphoma: more questions than answers. Int J Cancer 2009;124:1745-1755.
52. Schlee M, Schuhmacher M, Holzel M, Laux G, Bornkamm GW. c-MYC impairs immunogenicity of human B cells. Adv Cancer Res 2007;97:167-188. (Pubitemid 46546594)
53. Petersdorf SH, Wood DE. Lymphoproliferative disorders presenting as mediastinal neoplasms. Semin Thorac Cardiovasc Surg 2000;12:290-300.
54. Vacca A, Ribatti D, Roncali L, Dammacco F. Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Leuk Lymphoma 1995;20:27-38. (Pubitemid 26007426)
55. Pals ST, de Gorter DJ, Spaargaren M. Lymphoma dissemination: the other face of lymphocyte homing. Blood 2007;110: 3102-3111. (Pubitemid 350106300)
56. Gomez TS, Billadeau DD. T cell activation and the cytoskeleton: you can't have one without the other. Adv Immunol 2008;97:1-64. (Pubitemid 351711631)
57. Billadeau DD, Nolz JC, Gomez TS. Regulation of T-cell activation by the cytoskeleton. Nat Rev Immunol 2007;7:131-143. (Pubitemid 46174860)
58. Stradal TE, Pusch R, Kliche S. Molecular regulation of cytoskeletal rearrangements during T cell signalling. Results Probl Cell Differ 2006;43:219-244. (Pubitemid 44445586)
59. Acuto O, Cantrell D. T cell activation and the cytoskeleton. Annu Rev Immunol 2000;18:165-184. (Pubitemid 30365378)
60. del Pozo MA, Nieto M, Serrador JM, et al. The two poles of the lymphocyte: specialized cell compartments for migration and recruitment. Cell Adhes Commun 1998;6:125-133.
61. Sumoza-Toledo A, Santos-Argumedo L. The spreading of B lymphocytes induced by CD44 cross-linking requires actin, tubulin, and vimentin rearrangements. J Leukoc Biol 2004; 75:233-239. (Pubitemid 38174579)